Overview
Provider of industrial materials and life science solutions.
Founded
1947
Deals · 12mo
0
Links
Stage focus
Geographic focus
Sector focus
Investment portfolio
- Toregem BioPharma
Participated · Series A · Jul 2023
Toregem BioPharma is developing TRG-035, an experimental antibody therapy designed to neutralize USAG-1, a protein that suppresses tooth formation, with the goal of reactivating dormant tooth buds and prompting natural tooth development. The company’s initial clinical focus is on patients with congenital tooth agenesis, with broader potential envisioned for stimulating a “third dentition” to treat tooth loss from aging, decay, or injury. Preclinical evidence of tooth regeneration has come primarily from animal studies (mice), while human testing to date has focused on safety. Toregem launched a Phase I trial at Kyoto University Hospital in October 2024 that enrolled 30 healthy adult men missing at least one molar; recruitment was reported to have stopped by March 2026 and the study is operationally complete, though full results have not been published. Toregem has secured a mix of equity financing and non-dilutive support (grants and subsidies) and reports cumulative funding above $29 million. The company is using its recent Pre-Series C proceeds to advance Phase II trials in Japan and to prepare for clinical development in the United States.
- Flylab
Led · Seed · Dec 2022
Flylab produces insect-based ingredients using black soldier fly (BSF) larvae for animal feed, targeting aquafeed and pet food manufacturers. The company closed a USD 1 million seed and pre-Series A financing in 2022 led by Sanyo Trading to help scale commercial operations. It was previously co-financed by ALES Global Investment Partnership III and MSIVC2021V Venture Capital Investment Limited Partnership to build its first BSF pilot plant in northern Thailand. Rising conventional feed costs have increased demand for BSF meal, and Flylab reports a large amount of inbound interest and signed contracts covering full production capacity for the next three years. The company plans to raise a USD 15 million Series A in 2023 to build its first industrial-scale factory in Bangkok to produce more than 6,000 MT of insect-based ingredients.